Advancements in HPV-Related Cancer Prevention and Treatment: Integrating Vaccination, Screening, and Therapeutic Innovations

Human papillomavirus (HPV) remains one of the most common and preventable causes of cancer globally. While most HPV infections are transient and resolve without intervention, persistent infection with high-risk strains can lead to malignancies in various anatomical sites, including the cervix, vulva, vagina, anus, penis, and oropharynx. Cervical cancer, in particular, accounts for the most significant burden of HPV-related cancers worldwide and is largely preventable through vaccination and routine screening.

This CME/CE course provides a comprehensive overview of HPV pathogenesis, cancer risk stratification, and the epidemiological impact of persistent HPV infection. Participants will explore prevention strategies, including the expanded role of HPV vaccination across genders, age groups, and immunocompromised populations. Emphasis is placed on population-specific cervical cancer screening protocols, the transition to HPV-based testing, and the growing role of self-sampling technologies to improve access and adherence.

The course also examines the latest treatment advances in HPV-related cancers. Topics include checkpoint inhibitors, PARP inhibitors, and antibody-drug conjugates—targeted therapies that are reshaping the landscape of advanced cervical cancer treatment. Learners will evaluate these therapies in light of updated NCCN guidelines and clinical trial data, and understand how to integrate them into real-world care plans.

With rising HPV vaccination coverage and expanding therapeutic options, healthcare providers across disciplines must be equipped with the latest knowledge to prevent, detect, and manage HPV-related malignancies. This activity bridges the gap between public health and precision oncology, offering actionable insights to reduce cancer burden and promote equity in cancer care.

Learning Objectives

After completing this activity, learners will be able to:

• Explain the pathogenesis of HPV infection and identify high-risk HPV strains associated with cervical and other HPV-related cancers.
• Implement evidence-based prevention strategies, including HPV vaccination schedules and cervical cancer screening recommendations.
• Evaluate and apply emerging therapeutic innovations such as immunotherapy, PARP inhibitors, and antibody-drug conjugates in the management of HPV-related cancers.

Who Should Do This Course?

This course is ideal for:

• OB/GYN specialists and gynecologic oncologists managing screening and treatment for cervical and related cancers.
• Family medicine and internal medicine physicians who coordinate preventive care and vaccination programs.
• Public health professionals and infectious disease clinicians focused on reducing HPV-related disease burden.
• Oncology nurses and clinical nurse specialists providing education and support for patients undergoing cancer treatment.
• Primary care providers aiming to improve patient adherence to HPV vaccination and screening protocols.

Did You Know?

• HPV causes nearly 100% of cervical cancer cases worldwide. (CDC, 2023)
• More than 90% of HPV-related cancers are preventable through vaccination and screening. (WHO, 2022)
• Only 54% of eligible individuals in the U.S. have completed the HPV vaccine series. (CDC National Immunization Survey, 2023)
• Self-sampling for HPV testing can increase cervical screening uptake by 50% in underserved populations. (The Lancet Public Health, 2022)
• The FDA approved the first antibody-drug conjugate for recurrent/metastatic cervical cancer in 2021. (FDA.gov, 2021)